Short Interest in Medicus Pharma Ltd (NASDAQ:MDCX) Expands By 24.4%

Medicus Pharma Ltd (NASDAQ:MDCX) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 1,105,825 shares, a growth of 24.4% from the January 15th total of 888,655 shares. Currently, 4.9% of the company’s shares are sold short. Based on an average daily trading volume, of 297,800 shares, the short-interest ratio is presently 3.7 days. Based on an average daily trading volume, of 297,800 shares, the short-interest ratio is presently 3.7 days. Currently, 4.9% of the company’s shares are sold short.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. May Hill Capital LLC bought a new position in shares of Medicus Pharma during the second quarter valued at approximately $107,000. Jane Street Group LLC purchased a new position in shares of Medicus Pharma during the 4th quarter worth approximately $92,000. Private Advisor Group LLC boosted its position in shares of Medicus Pharma by 3.8% during the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after purchasing an additional 5,500 shares in the last quarter. HRT Financial LP purchased a new position in Medicus Pharma during the fourth quarter valued at $42,000. Finally, Commonwealth Equity Services LLC increased its stake in shares of Medicus Pharma by 161.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after acquiring an additional 17,611 shares in the last quarter.

Medicus Pharma Trading Up 12.3%

Shares of MDCX stock traded up $0.14 during trading hours on Wednesday, hitting $1.24. 1,112,003 shares of the company’s stock were exchanged, compared to its average volume of 367,222. The company has a market capitalization of $31.55 million, a PE ratio of -0.57 and a beta of -1.17. The business’s 50 day simple moving average is $1.42 and its 200-day simple moving average is $1.96. Medicus Pharma has a 12-month low of $0.92 and a 12-month high of $8.94.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Medicus Pharma in a research note on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $27.00 price target on shares of Medicus Pharma in a research note on Monday, December 15th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $23.50.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.